VLON Vallon Pharmaceuticals, Inc.

Vallon Pharmaceuticals, Inc. engages in developing and manufacturing medicines for attention-deficit/hyperactivity disorder (ADHD) and narcolepsy disorder. The company was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

$5.13
As of 06/21/2021     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  02/10/2021
Outstanding shares:  6,812,836
Average volume:  168,942
Market cap:   $36,380,544
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    92023M101
ISIN:        US92023M1018
Sedol:      BMZ4LK7

---

Valuation   (See tab for details)

---

PE ratio:   -30.29
PB ratio:   2.91
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%